Alpha Cancer is targeting three key market opportunities with AFP:
Immuno-Oncology | ACT-903 (AFP + Linker + Maytansine) – Targets on most solid and liquid tumors and myeloid-
derived suppressor cells (MDSCs)
Radio Labelled Theranostics – 89Zr-ACT-101 (Diagnostic) and 177Lu-ACT-101 (Therapeutic)
Immunomodulation | ACT-101 (AFP) – Polyindication Drug (Portfolio in a Product) – IBD (Crohn’s/Colitis), MG, Multiple
Sclerosis and 40+ other IgG-driven disease – (seeking to outlicense this platform).